Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
Lupin recognized the need to digitize more applications, improve scalability, decrease risk of security breaches and eliminate critical data loss
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Upon closing, the Quakertown business will become an independent company called Microsize
This newly designed small-format detector is made up of caesium iodide technology and is extremely high in resolution, capable of capturing the fine detail of smaller anatomical structures present in paediatric patients
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Subscribe To Our Newsletter & Stay Updated